

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**Form 8-K**

**Current Report**

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **July 10, 2014**

**TRANSBIOTEC, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**000-53316**

(Commission  
File Number)

**26-0731818**

(I.R.S. Employer  
Identification No.)

**400 N. Tustin Ave., Suite 225**

**Santa Ana, CA 92705**

(Address of principal executive offices) (zip code)

**(949) 285-9454**

(Registrant's telephone number, including area code)

**194 Marina Drive, Suite 202**

**Long Beach, CA 90803**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## **Section 1 – Registrant’s Business and Operations**

### **Item 1.01 Entry into a Material Definitive Agreement**

On July 10, 2014, we entered into a Master Distribution Agreement with A.G. Global Capital (“A.G. Global”), pursuant to which A.G. Capital will be the exclusive distributor of our SOBR alcohol testing device in the Republic of Turkey (“Turkey”), the Kingdom of Sweden (“Sweden”) and the Gulf Cooperation Council (“GCC”) comprising Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates, the Republic of Azerbaijan.

## **Section 7 – Regulation FD**

### **Item 7.01 Regulation FD Disclosure.**

On September 10, 2014, we issued a press release announcing the Master Distribution Agreement with A.G. Global Capital. A copy of the press release is furnished with this Current Report as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under such section, nor shall it be deemed incorporated by reference in any of our filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

## **Section 9 – Financial Statements and Exhibits**

### **Item 9.01 Financial Statements and Exhibits**

(c) Exhibits

99.1	Press release dated September 10, 2014 issued by TransBiotec, Inc., announcing the signing of a Master Distribution Agreement with A.G. Capital Group.
------	--

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TransBiotec, Inc.**  
**a Delaware corporation**

Dated: September 12, 2014

*/s/ Charles Bennington*  
\_\_\_\_\_  
By: Charles Bennington  
Its: President

**TransBiotech, Inc. Announces the Signing of a Master Distribution Agreement with AG Global Capital**

09/10/2014 Press Release

***SUB HEAD: TransBiotech, Inc. Enters into a Master Distribution Agreement for Distribution Rights to the SOBR Alcohol Testing Device***

SANTA ANA, CA., September 10, 2014 -- TransBiotech, Inc. (OTCBB:IMLE) today announced that it has entered into a Master Distribution Agreement with AG Global Capital to distribute TransBiotech, Inc.'s SOBR alcohol testing device in the Republic of Turkey ("Turkey"), the Kingdom of Sweden ("Sweden") and the Gulf Cooperation Council ("GCC") comprising Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates, the Republic of Azerbaijan.

The Master Distribution Agreement (MDA) is the result of negotiations between the parties and details the basic outline of the rights AG Global Capital would have as TransBiotech's exclusive distributor of the SOBR device in Turkey, Sweden and the GCC. Under the MDA, AG Global Capital would be TransBiotech's exclusive distributor in the countries of Turkey, Sweden and the GCC for a period of 10 years, based on performance criteria, beginning on July 10, 2014, with AG Global Capital concentrating on selling the SOBR device through its affiliate distributors.

**About TransBiotech, Inc.**

TransBiotech, Inc. has developed and patented a non-invasive alcohol sensing system ("SOBR") which includes an ignition interlock. The alcohol sensing system offers a unique solution to the national drunk driving problem that can now be applied to new markets. SOBR consists of two parts: an ethanol alcohol detection system and an ignition interlock device connected through a microprocessor. SOBR detects the ethanol alcohol level of the operator and does not allow the vehicle or equipment to start if the Blood Alcohol Concentration (BAC) is above a preset limit. In addition, random real-time monitoring also ensures that the operator cannot continue to operate a vehicle with an unsafe BAC.

**About AG Global Capital**

AG Global Capital is a diverse financial and advisory company, located in Newport Beach, CA. The principals have decades of experience in international markets in both manufacturing, distribution and financing. AG Global Capital has formed a marketing and distribution arm specifically to market and sell TransBioTec's SOBR product in Turkey, Sweden and the GCC.

**Forward Looking Statement**

TransBiotech, Inc.'s statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in TransBiotech, Inc.'s filings with the Securities and Exchange Commission, including TransBiotech, Inc.'s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

**CONTACT INFORMATION**

Charles Bennington, President  
TransBioTec, Inc.

Telephone: (949) 285.9454  
Email: [cbennington@transbiotec.com](mailto:cbennington@transbiotec.com)  
URL: <http://www.TransBiotech.com/>